Ritalin / Methylphenidate

What Is Methylphenidate?

Methylphenidate is a pharmaceutical agent with stimulating effects. It belongs to the amphetamine-like substances and is primarily used for the medicinal treatment of Attention Deficit Hyperactivity Disorder (ADD/ADHD).

Additionally, methylphenidate is used for:

Narcolepsy
Augmentation of antidepressants in treatment-resistant depression

Brand Names

Methylphenidate has been in use since 1959. In Germany it is marketed under various names:

Ritalin, Ritalin SR, Ritalin LA
Medikinet, Medikinet retard
Concerta
Methylphenidat Hexal
and other generics

Differences Between Preparations

All preparations contain the same active ingredient but differ in:

Fillers and additives
Duration of action (immediate vs. extended-release forms)
Release mechanism

In extended-release medications, the active ingredient is released in a time-delayed and continuous manner throughout the day via depot systems.

Mode of Action

Methylphenidate inhibits the reuptake of dopamine and noradrenaline into the presynaptic terminals, thereby increasing their concentration in the synaptic cleft.

This leads to:

Increased signal activity at the receptor
Elevation of sympathetic tone
To a minor degree: release of catecholamines

Hypotheses Regarding the Effect in ADHD

Hypothesis 1: Frontal Brain Activation

In ADHD, certain areas of the frontal brain that control impulses are less active. Stimulants activate these areas, enabling the brain to better perform its control functions.

Hypothesis 2: Dopamine Transporter Blockade

People with ADHD exhibit an increased number and activity of dopamine transporters. This reuptake system of the nerve cells absorbs the released dopamine like a “vacuum cleaner.” Methylphenidate temporarily blocks this system (3-5 hours) and thus improves dopamine availability.

Hypothesis 3: Plasticity Hypothesis

In the affected brain areas, there are too few receptors for dopamine. Through methylphenidate, the receptors are supplied with more dopamine, so that signal transmission functions better.

Dosage

Adjustment (Titration Method)

Start with a low single dose (2.5 or 5 mg)
Weekly increase by 5-10 mg
Adjustment based on observation forms
After several months, readjustment may be necessary

Typical Dosages

Age Group	Single Dose	Daily Dose	Frequency
Children from 6 years	5 mg (start)	10-40 mg	1-3x daily
Adults	10 mg (start)	20-30 mg (up to 60 mg)	2-3x daily

Duration of Action

Regular tablets: 3-4 hours (sometimes longer)
Extended-release forms: 6-8 hours
Onset of action: 15-30 minutes

Important Notes

Children should not be treated before age 6 (exceptions only with strict indication)
Previously, intake was recommended only on school days - today continuous administration is preferred
Administration of methylphenidate alone is usually not sufficient - multimodal therapy is recommended

Side Effects

Most side effects are limited to the adjustment phase and are short-lived.

Appetite

Common: Decrease in appetite
Can be mitigated by taking after meals
Shift main meal to the evening
Usually resolves within several months

Gastrointestinal Complaints

Nausea when taken without fluids
Occasional stomach pain or vomiting at the beginning
Improvement when taken with meals

Sleep Disturbances

Can occur with too high a dose
Also with too late administration of the last dose
Often subside over the course of several weeks

Psychological Side Effects

Temporary sensitivity, especially in children
Feeling of being “completely different” or “no longer oneself”
Rarely: depressive states
Important: With concurrent depression, monitor for suicidality (especially first 3 weeks)

Cardiovascular System

Blood pressure increase
Increased heart rate (especially in children)
With pre-existing conditions: strict indication and close monitoring required

Rebound Effect

After the end of the duration of action, ADHD symptoms may temporarily intensify.

Risk of Dependence

Abuse Potential

As a street drug (snorted/injected) it can lead to addiction
At therapeutic doses: no notable addiction potential
Risk with abuse: possible talc embolism from tablet fillers

Discontinuation

Abrupt discontinuation can lead to temporary hyperactivity, irritability, or depressive mood
Recommendation: Gradually reduce dose over the course of one week

Overdose

Severity	Symptoms
Mild	Dizziness, palpitations, increased alertness
Moderate (double dose)	Dizziness, elevated blood pressure, sleep problems
Severe	CNS hyperexcitability, seizures, delirium to coma, cardiac arrhythmias

Drug Interactions

Contraindicated

MAO inhibitors - must not be combined!

Caution With

Antihypertensives (especially guanethidine)
Coumarin-type anticoagulants
Antiepileptics (phenobarbital, phenytoin, primidone)
Neuroleptics
Tricyclic antidepressants
Antacids - do not take simultaneously
Alcohol - should be avoided during treatment

Alternatives to Methylphenidate

Amphetamine Preparations

For patients who do not respond adequately to methylphenidate or develop depressive moods:

Can be promising for comorbid aggressive behavioral disorders
For tic disorders under methylphenidate: high probability that these will not occur with amphetamine sulfate
Favorable for social disorders
For ADHD with borderline disorder: low dose (1-2 mg daily) frequently shows mood-stabilizing effect

Atomoxetine (Strattera)

Noradrenaline reuptake inhibitor (not a stimulant)
Available in Germany since March 2005
Onset of action: Only assessable after several weeks
Standard dosage: 1.2 mg/kg body weight
Advantage: No dependence potential
Disadvantage: Newer substance, limited long-term data

Tricyclic Antidepressants

As alternatives without dependence risk:

Active Ingredient	Average Dose	Improvement Rate
Desipramine	183 mg/d	68%
Nortriptyline	92 mg/d	68%

Lower doses are also effective in many patients.

Further Alternatives

Reboxetine (Edronax, Solvex)
Imipramine - good results in adults
Venlafaxine - positive effects in open studies
Beta-blockers (propranolol, nadolol) - less established

Off-Label Use

Situation for Adults

For adults as well, methylphenidate represents the first-choice medication. However:

Currently, no preparation is approved for adults in Germany
Can be prescribed by a physician within the framework of a therapeutic trial
Cost coverage with some health insurers is not yet clarified
In Switzerland, methylphenidate is covered by health insurance for adults as well

Conditions for Cost Coverage (BSG)

Life-threatening or condition sustainably impairing quality of life
No other approved medication available on the market
Published evidence regarding quality and efficacy

History

Methylphenidate was first synthesized in 1944 by Leandro Panizzon, an employee of the Swiss company Ciba (now Novartis).

Managing Side Effects

Side Effect	Measures
Appetite reduction	Take medication with meals; high-calorie nutrition in the evening; no forced eating
Stomach pain	Small, more frequent meals
Insomnia	Check sleep hygiene; last dose in the afternoon; consider extended-release forms
Sadness	Reduce dose; extended-release forms; consider antidepressants
Rebound effect	Extended-release forms; overlapping dosing
Irritability	Review diagnosis; rule out overdose
Anxiety	Slow dose titration; dose reduction